In May 2024, Knight entered into an agreement with Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Ironshore Therapeutics, Inc. (now part of Collegium Pharmaceutical, Inc.; ...
ADHD is not a disease but a malfunctioning composition of cognitive traits that exist on more functional levels even in the general population, such as “attention control” (concentration) and ...
Introduction Attention-deficit/hyperactivity disorder (ADHD) is one of the most prevalent neurodevelopmental disorders and is a persistent pattern of inattention and ...
Elite received approval from the Food and Drug Administration for a generic version of Vyvanse (lisdexamfetamine dimesylate) capsules in strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg ...
Attention deficit hyperactivity disorder: pharmacological and psychological interventions in children, young people and adults.2008. London: The British Psychological Society and the Royal College ...
Attention deficit hyperactivity disorder (ADHD) affects around 1–3% of children. There is a high level of comorbidity with developmental and learning problems as well as with a variety of psychiatric ...
Adults with attention-deficit/hyperactivity disorder (ADHD) are more frequently presenting for diagnosis and treatment. Medication is considered to be appropriate ...